Radiofrequency Ablation for Treatment of Refractory Gastric Antral Vascular Ectasia: A Systematic Review of the Literature

Table 2

Current available evidences on treatment of GAVE with radiofrequency ablation.

Author	Year	Study level	Sample	RFA system	Average sessions	Technical success	Clinical success	AEs	Follow-up (months)
Gross et al. [24]	2008	Prospective open-label single center	6	HALO^90	Mean 1.7, range (1–3)	6/6 (100%)	5/6 (83%)	None	2
							Mean Hb gain 8.6 → 10.2
McGorisk et al. [25]	2013	Prospective open-label single center	21	HALO^ULTRA	Median 2, range (1–3)	19/21 (90%)	18/21 (86%)	2/21 (9.5%)	6
							Mean Hb gain 7.8 → 10.2
Jana et al. [26]	2015	Prospective open-label single center	7	HALO^ULTRA	Median 2, range (1–3)	7/7 (100%)	5/7 (71%)	None	6
							Mean Hb gain 9.3 → 10.1
Raza and Diehl [27]	2015	Prospective open-label single center	9	HALO^90	Median 3, range (2–6)	9/9 (100%)	6/9 (67%)	None	11
							Mean Hb gain 7.3 → 10.5
Dray et al. [28]	2014	Retrospective multicentric	24	HALO^90 or HALO^ULTRA	Mean 1.8 ± 0.8	Not reported	15/24 (62%)	None	6
							Mean Hb gain 6.8 → 9.8
Thandassery et al. [29]	2014	Case report	1	HALO^90	2	Yes	Yes	None	1
							Hb gain 8 → 12
Islam et al. [30]	2014	Case report	1	HALO^TTS	1	Yes	Yes	None	1
							Hb gain 6→ 10.7
Ibáñez-Sanz et al. [31]	2015	Case report	1	HALO^90	2	Yes	Yes	None	3
							Hb gain 7.5 →12
Trindade et al. [32]	2016	Case report	1	HALO^Nd	3	Yes	Not reported	None	6
Gaslightwala et al. [33]	2014	Case report	1	HALO^90	4	Not reported	Not reported	Yes	Not reported

Technical success: feasibility of therapy and complete endoscopic ablation of GAVE; clinical success: hemoglobin improvement and complete independence from the need for transfusions after follow-up; RFA: radiofrequency ablation; AEs: adverse events.